RGC
Regencell Bioscience Holdings Limited (NASDAQ)
Healthcare — Drug Manufacturers - Specialty & Generic
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
None
$8.03
+$1.94 (+31.86%)
Sign in to add RGC to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $3.97B |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.01 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -177.66% |
| Debt/Equity | 31.68 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 14.4 |
| Beta | 1.64 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $69.00 |
| 52-Week Low | $5.80 |
| 50-Day Avg | $22.17 |
| 200-Day Avg | $22.23 |
| Avg Volume | 187.7K |
| Volume | $2.54M |
Performance Analysis
NEUTRALRGC presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($5.80), which could present a value opportunity.
+
RSI at 14.4 signals oversold conditions — a bounce may be ahead.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:29 UTC
Back to Screener Export Report